Navigation Links
Watson Completes Acquisition of CRINONE® and PROCHIEVE® Product Line and Shares of Columbia Laboratories
Date:7/2/2010

ors affecting the acquisition or Watson's business. These factors include, among others, the risk of not completing the acquisition for any reason, including as result of third party intervention; successful integration of the Columbia products and product rights; the impact of competitive products and pricing; timely and successful consummation and implementation of strategic initiatives; the timing and success of product launches; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; costs and efforts to defend or enforce intellectual property and contractual rights; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson, their third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report for the year ended December 31, 2009 and quarterly report for the period ended March 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )

(Logo:

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015   HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of advanced ... Godshall , is scheduled to present at the Bank of ... Las Vegas on Thursday, May 14, 2015, at ... webcast of the Company,s presentation at the conference will be ...
(Date:5/4/2015)... 4, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXI Rx ... of the agreement, Isis is eligible to receive up ... $100 million up-front payment and a $55 million payment ... study in patients with compromised kidney function. Isis is ...
(Date:5/4/2015)... , May 4, 2015 MEI Pharma, ... focused on the clinical development of novel therapies ... mitochondria-specific effects of the Company,s investigational drug candidate ... activity when combined with a tyrosine-kinase inhibitor (TKI). ... to be a potent inhibitor of mitochondrial oxidative ...
Breaking Medicine Technology:HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5
... , FRANKLIN LAKES, N.J. , ... BDX ), a leading global medical technology company, is increasing ... Haiti earthquake relief efforts from the $500,000 ... in market value of critical medical supplies.  This additional commitment will ...
... , Jan. 27 CardioGenics Holdings Inc. (OTC ... the in-vitro diagnostics segment of the Point-Of-Care (POC) diagnostic market, ... self-metering cartridge for its POC diagnostic device, the QL Care ... the self-metering cartridge. , Dr. Yahia Gawad , CEO ...
Cached Medicine Technology:BD Increases Haiti Relief Fund to Include $5 Million in Product Donations 2BD Increases Haiti Relief Fund to Include $5 Million in Product Donations 3CardioGenics Announces Completion of Cartridge Design for QL Care Analyzer 2CardioGenics Announces Completion of Cartridge Design for QL Care Analyzer 3
(Date:5/4/2015)... 2015 “ Food Cost Calculator ” was ... takes a look at the latest and coolest applications on ... host of AppWatch and technology expert, conducted the app review ... to manage and efficiently calculate food costs. , The restaurant ... fact, the industry has an estimated 1.8 trillion dollar impact ...
(Date:5/4/2015)... 2015 The Accreditation for ... first-ever congenital heart disease (CHD) standards for ... accreditation. Driven by the latest available clinical ... review of interventional procedures in pediatric patients ... “The ACE CHD Standards for PCCL Accreditation, ...
(Date:5/4/2015)... “St. Louis has long represented opportunity ... West,” so it is the perfect place for Zerorez ... Ben Litalien, Chief Development Officer for Zerorez. “We ... will provide veterans with a $10,000 discount on our ... have a number of Military Veterans in its ranks ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Sara Soulati, ... physician practice management firm in Los Angeles associated with ... the patent-pending status of The Sara Soulati Health For ... in 2010, is a lifestyle modification and disease prevention ... 2015 to the U. S. Patents and Trademarks Office ...
(Date:5/3/2015)... Barbara Crone has joined Women’s Excellence in ... of the men, women and families who seek her care, initially ... for families in the home. , “When the ... if I could complete their care with the delivery of their ... mentor Nurse Midwife, I knew it was time for me to ...
Breaking Medicine News(10 mins):Health News:An Application to Manage a Successful Restaurant Was Featured on NewsWatch Television 2Health News:Accreditation for Cardiovascular Excellence (ACE) Publishes New Standards for Pediatric and Adult Congenital Cardiac Catheterization Laboratories 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 3Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2Health News:Women's Excellence In Midwifery Welcomes Barbara Crone 2
... out on the best drug treatment for their disease, because ... of print in the Archives of Disease in Childhood. ... and the disease prompts up to a third of children ... , The researchers used national data to calculate the number ...
... CINCINNATI, Sept. 3 Most children in the ... Attention Deficit,Hyperactivity Disorder (ADHD) have not been diagnosed ... medications, according to the first,national ADHD prevalence study ... criteria, according to a new study conducted by ...
... appears to be associated with adolescents risk of becoming ... in their lifetimes, according to a report in the ... one of the JAMA/Archives journals. , Previous studies have ... risk of starting to smoke, according to background information ...
... the medications they need, researchers say , , MONDAY, Sept. ... children have attention-deficit/hyperactivity disorder (ADHD), but only 32 percent ... That,s the sobering conclusion of a landmark new study, ... consider the "gold standard" of diagnostic criteria -- the ...
... Stent is Featured at ... ESC Congress 2007, ... from patient subsets of a global registry support,the use of the ... Presented today by Robbert de Winter, M.D., Ph.D., at the European,Society ...
... Cam in Cambridge, famous as a haunt of students ... become the next generation of antibiotics, according to scientists ... for General Microbiologys 161st Meeting at the University of ... With antibiotics now over-prescribed for treatments of bacterial infections, ...
Cached Medicine News:Health News:Childhood asthma still inappropriately treated in the UK 2Health News:Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New 'Gold Standard' Study by Cincinnati Children's Researchers 2Health News:Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New 'Gold Standard' Study by Cincinnati Children's Researchers 3Health News:Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New 'Gold Standard' Study by Cincinnati Children's Researchers 4Health News:Teens who see more smoking in movies may have increased risk of becoming established smokers 2Health News:9% of U.S. Kids Have ADHD 2Health News:9% of U.S. Kids Have ADHD 3Health News:Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents 2Health News:New viruses to treat bacterial diseases -- 'My enemies' enemy is my friend' 2
#2 10 mm hook. Flat serrated handle with polished finish. Overall length: 5.5 inches....
Curved shaft with flat 4.5 mm hook. Flat serrated handle with polished finish. Overall length: 5.3 inches....
Titanium. Small "H" shaped push-pull tip. Shaft angled 45 degrees, 9 mm from tip. Round knurled handle with dull finish. Overall length: 4.8 inches. Most popular size or model....
This suture adjuster facilitates post operative suture adjustment of running sutures while decreasing the possibility of suture damage or breakage....
Medicine Products: